• About
  • News
  • Projects
      Project 1 - Development of a Gene Therapy for Usher Syndrome Type 1B (USH1B)
        Project 2 - Evaluation of novel gene therapy approaches for USH2A
          Project 3 - Retina organoids as models for assessing pathomechanisms and effects of novel treatments inn retinal disorders
            Project 4 - Development of a one-time gene therapy for age-related macular degeneration
              Project 5 - Development of novel gene therapy strategies for treatment of autosomal dominant retinitis pigmentosa in a pig model
                Project 6 - Novel targets for gene therapy in diabetic retinopathy (DR)
                  Project 7 - RPE plasticity in the context of neurodegenerative disease: Understanding the limits, pushing the boundaries
                    Project 8 - Novel AI-based biomarkers for retinal gene therapy outcomes by integrating functional neuroimaging and retinal imaging
                      Project 9 - Integrating imaging, clinical and genetic data with machine learning to establish biomarkers for retinal diseases
                    • Project leaders
                    • Publications
                    1. DFG-Forschergruppe 5621
                    2. News
                    3. Dr. Moritz Lindner talked about optogenetics in the eye clinic in munich
                    News | 30/09/2025

                    Dr. Moritz Lindner talked about optogenetics in the eye clinic in munich

                    The Ocu-GT research group hosts an external spaker from Marburg

                    On September 17th, our research group hosted a successful talk by Dr. Moritz Lindner from the Institute of Physiology and Pathophysiology at the University of Marburg (see www.lindnerlab.de).

                    Dr. Lindner leads the Retinal Physiology and Gene Therapy research group, focusing on:

                    • The functional capacity of optogenetic vision restoration.
                    • The effect of ion channel subunits (like Kcnv2) on retinal signal processing.
                    • Signaling cascades initiated by melanopsin.

                    His 40-minute presentation at the LMU eye clinic's lecture hall specifically covered optogenetic gene therapy for vision restoration. The talk drew an engaged audience, including members of the Ocu-GT research group and other curious members of the eye clinic. It was followed by a vivid discussion about fundamental questions and recent publications in the field.

                    Afterward, Dr. Lindner and several members of the Ocular Gene Therapy research group continued their discussions over dinner at a nearby restaurant.

                    This event was a marks the first single talk by an invited external speaker in the history of our research group. We plan to host similar events in the future.


                    FOR 5621 Research unit

                    Coordination

                    Mathildenstr. 8
                    80336 Munich
                    +49 89 2180 77337
                    wüp64D12vim ful_vfiuyznius:nmi
                    Login for editors
                    Imprint | Data-Safety

                    DFG-Forscher...

                    • News
                    • Projects
                      • Project 1 - Development of a Gene Therapy for Usher Syndrome Type 1B (USH1B)
                      • Project 2 - Evaluation of novel gene therapy approaches for USH2A
                      • Project 3 - Retina organoids as models for assessing pathomechanisms and effects of novel treatments inn retinal disorders
                      • Project 4 - Development of a one-time gene therapy for age-related macular degeneration
                      • Project 5 - Development of novel gene therapy strategies for treatment of autosomal dominant retinitis pigmentosa in a pig model
                      • Project 6 - Novel targets for gene therapy in diabetic retinopathy (DR)
                      • Project 7 - RPE plasticity in the context of neurodegenerative disease: Understanding the limits, pushing the boundaries
                      • Project 8 - Novel AI-based biomarkers for retinal gene therapy outcomes by integrating functional neuroimaging and retinal imaging
                      • Project 9 - Integrating imaging, clinical and genetic data with machine learning to establish biomarkers for retinal diseases
                    • Project leaders